SCHEMBL342435

SCHEMBL342435

O=S(=O)(O)CCN1CCNCC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
HSD17B10 Q99714 1/20 0.41
CXCR4 P61073 2/20 0.41
LOX P28300 2/20 0.38
LMNA P02545 1/20 0.37
CYP3A4 P08684 1/20 0.37
GABRA1 P14867 1/20 0.37
TSHR P16473 1/20 0.37
GABRG2 P18507 1/20 0.37
NFKB1 P19838 1/20 0.37
GABRB3 P28472 1/20 0.37
GABRA5 P31644 1/20 0.37
GABRA3 P34903 1/20 0.37
GABRA2 P47869 1/20 0.37
GABRA6 Q16445 1/20 0.37
ANPEP P15144 1/20 0.37
ERAP2 Q6P179 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10823165 0.98 POLB (0.41) POLBSMN1; SMN2HSD17B10CXCR4LOX
SCHEMBL7618304 0.98 POLB (0.41) POLBSMN1; SMN2HSD17B10CXCR4LOX
Potassium Ion SCHEMBL28852047 0.96 POLB (0.39) POLBSMN1; SMN2HSD17B10CXCR4LOX
Water SCHEMBL28459309 0.96 POLB (0.39) POLBSMN1; SMN2HSD17B10CXCR4LOX
SCHEMBL28248770 0.92 POLB (0.37) POLBSMN1; SMN2HSD17B10CXCR4LOX
Piperazine SCHEMBL28819458 0.91 LMNA (0.37) POLBSMN1; SMN2HSD17B10CXCR4LOX
SCHEMBL2511955 0.91 ALDH1A1 (0.37) POLBSMN1; SMN2HSD17B10CXCR4LOX
SCHEMBL1007938 0.91 ALDH1A1 (0.37) POLBSMN1; SMN2HSD17B10CXCR4LOX
SCHEMBL3294493 0.91 ALDH1A1 (0.37) POLBSMN1; SMN2HSD17B10CXCR4LOX
SCHEMBL1647095 0.88 CXCR4 (0.47) POLBSMN1; SMN2HSD17B10CXCR4LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 907 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260077092-A1 INJECTABLE COLLAGEN IMPLANTS AND COMPOSITIONS AND RELATED SYSTEMS, AND METHODS OF PREPARATION AND USE THEREOF Miach Orthopaedics, Inc. (US) 2026-03-19 US claimed
EP-4654940-A1 ANNEALED MICROGEL PARTICLE SYSTEMS AND METHODS Tempo Therapeutics, Inc. (US) 2025-12-03 EP claimed
WO-2025122978-A1 CELL CRYOPRESERVATION AND DELIVERY VEHICLE AND METHODS OF USING THE SAME BLUEROCK THERAPEUTICS LP (US) 2025-06-12 WO claimed
WO-2025056716-A1 KITS AND METHODS FOR PRESERVATION OF BIOLOGICAL SAMPLES Technische Universität München, in Vertretung des Freistaates Bayern (DE) 2025-03-20 WO claimed
EP-4408174-A1 OPTIMIZED WATER LINE DELIVERY OF MICROBES International N&H Denmark ApS (DK) 2024-08-07 EP claimed
WO-2024159142-A1 ANNEALED MICROGEL PARTICLE SYSTEMS AND METHODS TEMPO THERAPEUTICS, INC. (US) 2024-08-02 WO claimed
WO-2024118032-A1 SPERM WASHING AND SPERM FREEZING SOLUTIONS ENRICHED WITH QUERCETIN ISTANBUL MEDIPOL UNIVERSITESI TEKNOLOJI TRANSFER OFISI ANONIM SIRKETI (TR) 2024-06-06 WO claimed
WO-2024107917-A1 SYNTHETIC ENAMEL AND USES THEREOF TRUSTEES OF BOSTON UNIVERSITY (US) 2024-05-23 WO claimed
WO-2024057324-A1 PLASMA-ACTIVATED COMPOSITIONS AND METHODS OF USE THEREOF NOVA PLASMA LTD. (IL) 2024-03-21 WO claimed
WO-2024047639-A1 INDOLIUM-BASED STABILIZERS OF HYDROPHOBIC DRUGS TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) 2024-03-07 WO claimed
EP-1033913-A1 ZWITTERIONIC FATTY ACID COMPOUNDS FOR ANTI-INFLAMATION Pugliese, Peter T. (US) 2000-09-13 EP claimed
WO-1999051204-A1 OCULAR IRRIGATING SOLUTION UNIVERSITY OF BRISTOL (GB) 1999-10-14 WO claimed
WO-1999027791-A1 ZWITTERIONIC FATTY ACID COMPOUNDS FOR ANTI-INFLAMATION PUGLIESE PETER T (US) 1999-06-10 WO claimed
EP-0396584-B1 ASSAY OF SALICYLATES OR REDUCED PYRIDINE NUCLEOTIDES MICROBIOLOGICAL RES AUTHORITY (GB) 1995-01-25 EP claimed
EP-0228239-B1 PREPARATION OF A MEDICAMENT FOR ARTHRITIS AND RHEUMATISM O'Sullivan, Donncha (IE) 1993-07-28 EP claimed
WO-1992006383-A1 DILUENT AND METHOD FOR DETERMINATION OF TOTAL CALCIUM BECKMAN INSTRUMENTS, INC. (US) 1992-04-16 WO claimed
US-4753942-A Method for the treatment of inflammatory conditions SULLIVAN DONNCHA O (IE) 1988-06-28 US claimed
EP-0228239-A2 Preparation of a medicament for arthritis and rheumatism O'Sullivan, Donncha (IE) 1987-07-08 EP claimed
EP-0100827-B1 PHARMACEUTICAL COMPOSITION CONTAINING AN ALIPHATIC AMINOSULPHONIC ACID ROSICAL LIMITED (IE) 1986-09-03 EP claimed
EP-0100827-A1 Pharmaceutical composition containing an aliphatic aminosulphonic acid ROSICAL LIMITED (IE) 1984-02-22 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260077092-A1 INJECTABLE COLLAGEN IMPLANTS AND COMPOSITIONS AND RELATED SYSTEMS, AND METHODS OF PREPARATION AND USE THEREOF COL2A1, COL1A1, MMP1 POLB 4565/4885SMN1; SMN2 1082/4885HSD17B10 1394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.